Determination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents Versus Biolimus A9-eluting Stents
Determination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents Versus Biolimus A9-eluting Stents: Retrospective and Prospective Follow-up Study for Patients Who Were Enrolled in the Previous DETECT-OCT Study
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
Studientyp
Studientyp
Einschreibung (Voraussichtlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
-
Seoul, Korea, Republik von, 120-752
- Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- 1. patients who were enrolled in the previous DETECT-OCT study
- 2. Patients who agreed with informed consents
Exclusion Criteria:
- 1. Patients who disagreed with informed consents
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
OCT-guided group
OCT-guided PCI with EES or BES
|
|
Angiography-guidance group
Angio-guided PCI with EES or BES
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall survival
Zeitfenster: At 5 years
|
Free from death
|
At 5 years
|
|
Overall survival
Zeitfenster: At 10 years
|
Free from death
|
At 10 years
|
|
Cardiac death
Zeitfenster: At 5 years
|
Within 30 days after intervention, deaths due to myocardial infarction, cardiac perforation, tamponade or arrhythmia or death associated with intervention, death due to complications of intervention, and major cardiovascular deaths that can not be ruled out by a judgment of the screening adverse reaction review committee.
|
At 5 years
|
|
Cardiac death
Zeitfenster: At 10 years
|
Within 30 days after intervention, deaths due to myocardial infarction, cardiac perforation, tamponade or arrhythmia or death associated with intervention, death due to complications of intervention, and major cardiovascular deaths that can not be ruled out by a judgment of the screening adverse reaction review committee.
|
At 10 years
|
|
Myocardial infarction
Zeitfenster: At 5 years
|
(Non-Q-wave and Q-wave) due to occlusion of the target lesion or severe restenosis.
The criteria for classification and diagnosis of myocardial infarction follow the Academic Research Consortium and the Third Universal Definition of MI.
Coronary intervention Clinically significant myocardial infarction following the procedure has recently been defined by the Society for Cardiovascular Angiography and Interventions (SCAI)
|
At 5 years
|
|
Myocardial infarction
Zeitfenster: At 10 years
|
(Non-Q-wave and Q-wave) due to occlusion of the target lesion or severe restenosis.
The criteria for classification and diagnosis of myocardial infarction follow the Academic Research Consortium and the Third Universal Definition of MI.
Coronary intervention Clinically significant myocardial infarction following the procedure has recently been defined by the Society for Cardiovascular Angiography and Interventions (SCAI)
|
At 10 years
|
|
Target lesion revascularization
Zeitfenster: At 5 years
|
Repeatedly performing percutaneous intervention or target bypass repeatedly to the target lesion due to restenosis or other complications of the target lesion.
The target lesion is defined as a treated segment of the vessel, ranging from 5 mm in the proximal portion of the stent to 5 mm in the distal portion of the stent.
|
At 5 years
|
|
Target lesion revascularization
Zeitfenster: At 10 years
|
Repeatedly performing percutaneous intervention or target bypass repeatedly to the target lesion due to restenosis or other complications of the target lesion.
The target lesion is defined as a treated segment of the vessel, ranging from 5 mm in the proximal portion of the stent to 5 mm in the distal portion of the stent.
|
At 10 years
|
|
Target vessel revascularization
Zeitfenster: At 5 years
|
Repeatedly performing percutaneous intervention or target bypass repeatedly to the target vessel due to restenosis or other complications of the target vessel.
|
At 5 years
|
|
Target vessel revascularization
Zeitfenster: At 10 years
|
Repeatedly performing percutaneous intervention or target bypass repeatedly to the target vessel due to restenosis or other complications of the target vessel.
|
At 10 years
|
|
Stent thrombosis
Zeitfenster: At 5 years
|
Based on the Academic Research Consortium (ARC) definition.
|
At 5 years
|
|
Stent thrombosis
Zeitfenster: At 10 years
|
Based on the Academic Research Consortium (ARC) definition.
|
At 10 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Voraussichtlich)
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Primärer Abschluss
Studienabschluss (Voraussichtlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 4-2018-1167
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .